Rxsight, Inc. Stock Price, News & Analysis

RxSight, Inc. (NASDAQ: RXST) announced that it will report its first quarter 2023 financial results on May 9, 2023, after market close. Management is set to discuss the results during a conference call beginning at 1:30 PM PT / 4:30 PM ET. This call aims to provide insights into the company’s financial performance and future outlook following their innovative advancements in ophthalmic medical devices, specifically their Light Adjustable Lens system designed for cataract surgery. The technology is unique as it allows for post-surgery adjustments to optimize patients' vision quality. Interested investors can register for the call and access it via a live and archived webcast.

RxSight, Inc. (NASDAQ: RXST) announced that its Light Adjustable Lens™ (LAL) system will feature in various surgeon presentations at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego from May 5-8, 2023. Key topics include:

• Presbyopia Correction - Neda Shamie, MD on May 5.
• Small Aperture Technology Integration - Cathleen M. McCabe, MD on May 6.
• Corneal Astigmatism Outcomes - Multiple presenters on May 7.

Surgeons will also share their LAL experiences at RxSight's booth (#1911), with additional details available through their website. This technology is the only adjustable intraocular lens system, enhancing post-cataract surgery vision.

On April 5, 2023, RxSight, operating under the stock symbol RXST, announced its participation in the Needham Healthcare Conference. The management team will engage in a fireside chat on April 19, 2023, at 11:15 a.m. PT, accessible via a live and archived webcast on their investor relations website.

RxSight is an ophthalmic medical device company focused on enhancing vision after cataract surgery with its innovative RxSight Light Adjustable Lens system. This technology allows for custom adjustments post-surgery, providing patients with optimized visual outcomes. For more details, visit www.rxsight.com.

RxSight, Inc. (NASDAQ: RXST) reported robust financial growth in its fourth quarter and full year 2022 results. Fourth quarter revenue reached $16.1 million, marking a 91% increase from 2021, driven by a 27% rise in Light Delivery Devices (LDDs) sold and a remarkable 208% jump in Light Adjustable Lenses (LALs). Full year revenue was $49.0 million, up 117% from 2021. The company anticipates 2023 revenue between $78.0 million and $83.0 million, signaling potential growth of 59% to 69%. Despite a net loss of $(66.8) million for 2022, the gross profit margin improved to 43.5%.

RxSight, Inc. is set to participate in the upcoming Oppenheimer Healthcare Conference on March 13, 2023, at 7:00 a.m. PT / 10:00 a.m. ET. The company specializes in ophthalmic medical devices focused on providing customized vision solutions following cataract surgery. Their innovative RxSight^® Light Adjustable Lens (LAL^®) system is the first intraocular lens technology allowing post-surgery adjustments to enhance patient vision quality. Interested parties can access a live and archived webcast of the presentation through their investor relations website.

RxSight, Inc. (NASDAQ: RXST) announced it will release its fourth quarter and fiscal year 2022 financial results on March 6, 2023, following market close. Management will hold a conference call at 1:30 p.m. PT to discuss the results. Interested participants can register for the call and access the live webcast on the company’s investor relations page.

RxSight specializes in ophthalmic medical devices and offers the innovative RxSight Light Adjustable Lens system, the first adjustable intraocular lens technology, enhancing patient vision post cataract surgery.

RxSight, Inc. announced the successful closing of its public offering of common stock, selling 4,600,000 shares at $12.50 each, generating approximately $53.7 million in net proceeds after expenses. The offering included the full exercise of the underwriters' option to purchase an additional 600,000 shares. BofA Securities served as the sole bookrunning manager. This follows a previously filed shelf registration statement with the SEC on August 8, 2022. RxSight is focused on enhancing post-cataract surgery vision through its innovative Light Adjustable Lens technology.

RxSight, Inc. (NASDAQ: RXST) has announced a priced public offering of 4,000,000 shares of common stock at $12.50 each, aiming to raise approximately $50 million. The company has also granted underwriters a 30-day option to purchase an additional 600,000 shares. Proceeds will be directed towards commercial and marketing expansion, product development, research, and working capital needs. The offering is expected to close around February 10, 2023, subject to customary conditions. BofA Securities serves as the sole bookrunning manager for this public offering.

RxSight, Inc. (NASDAQ: RXST) announced plans for a public offering of $40 million in common stock. The company may grant underwriters a 30-day option to purchase an additional 15% of shares. Proceeds will fund commercial and marketing expansion, product development, and working capital. The offering will occur under a previously filed shelf registration statement. However, completion of the offering is subject to market conditions and cannot be guaranteed.

RxSight is focused on enhancing post-cataract surgery vision with its Light Adjustable Lens system, which allows customization of visual acuity.